Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 13/20 | 0.64 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | FABP4 | P15090 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | PTGIR | P43119 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3169551 | 0.93 | PTGDR2 (0.64) | PTGDR2PPARAPPARGFABP4FABP5 | |
| SCHEMBL3165034 | 0.93 | PTGDR2 (0.64) | PTGDR2PPARAPPARGFABP4FABP5 | |
| SCHEMBL3166645 | 0.92 | PTGDR2 (0.72) | PTGDR2PPARAPPARGFABP4FABP5 | |
| SCHEMBL3169518 | 0.90 | PTGDR2 (0.65) | PTGDR2PPARAPPARGFABP4FABP5 | |
| SCHEMBL3165575 | 0.90 | PTGDR2 (0.61) | PTGDR2PPARAPPARGFABP4FABP5 | |
| SCHEMBL3172580 | 0.89 | PTGDR2 (0.66) | PTGDR2PPARAPPARGFABP4FABP5 | |
| SCHEMBL3169197 | 0.89 | PTGDR2 (0.62) | PTGDR2PPARAPPARGFABP4FABP5 | |
| SCHEMBL3174329 | 0.89 | PTGDR2 (0.62) | PTGDR2PPARAPPARGFABP4FABP5 | |
| SCHEMBL3169556 | 0.88 | PTGDR2 (0.69) | PTGDR2PPARAPPARGFABP4FABP5 | |
| SCHEMBL3169291 | 0.86 | PTGDR2 (0.63) | PTGDR2PPARAPPARGPTGDRFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273745-B2 | Polycyclic acid compounds useful as CRTH2 antagonists and antiallergic agents | ASTELLAS PHARMA INC (JP) | 2012-09-25 | — | — | US | disclosed |
| EP-2094662-B1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC (JP) | 2012-04-11 | — | — | EP | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009991-A1 | POLYCYCLIC ACID COMPOUNDS USEFUL AS CRTH2 ANTAGONISTS AND ANTIALLERGIC AGENTS | HRH2, HRH1, HRH4 | PTGDR2 116/4885PPARA 1122/4885PPARG 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.